Human JAM-C Antibody

Catalog #: MAB1189
3 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB1189
MAB1189-SP

Detection of Human JAM‑C by Western Blot.

2 Images

All JAM-C Antibodies

Product Details

Citations (3)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human JAM-C Antibody Summary

Species Reactivity

Human

Specificity

Detects human JAM-C in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human JAM-A, recombinant mouse (rm) JAM-A, or rmJAM-C is observed.

Source

Monoclonal Mouse IgG₁ Clone # 208206

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human JAM-C
Val32-Asn241 (Ala149Pro)
Accession # Q9BX67

Formulation

Lyophilized from a 0.2 μm filtered solution in HEPES and NaCl with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

2 µg/mL

See below

Neutralization

Measured by its ability to neutralize JAM‑C-mediated adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line. Fong, S. et al. (2002) J. Immunol. 168:1618. The Neutralization Dose (ND₅₀) is typically 0.01-0.05 µg/mL in the presence of 0.2 µg/mL Recombinant Human JAM‑B Fc Chimera.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot

View Larger

Detection of Human JAM‑C by Western Blot. Western blot shows lysates of human placenta tissue, human brain tissue, JAR human choriocarcinoma cell line, and JEG-3 human epithelial choriocarcinoma cell line. PVDF membrane was probed with 2 µg/mL of Mouse Anti-Human JAM-C Monoclonal Antibody (Catalog # MAB1189) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for JAM-C at approximately 36-38 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Neutralization

View Larger

Cell Adhesion Mediated by JAM‑C and Neutralization by Human JAM‑C Antibody. Recombinant Human JAM-B/VE-JAM Fc Chimera, immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Human JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human JAM-C Monoclonal Antibody (Catalog # MAB1189). The ND₅₀ is typically 0.01-0.05 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: JAM-C

The family of juctional adhesion molecules (JAM), comprising at least three members, are type I transmembrane receptors belonging to the immunoglobulin (Ig) superfamily (1, 2). These proteins are localized in the tight junctions between endothelial cells or epithelial cells. Some family members are also found on blood leukocytes and platelets. Human JAM-C cDNA predicts a 310 amino acid (aa) residue precursor protein with a putative 31 aa signal peptide, a 210 aa extracellular region containing two Ig domains, a 23 aa transmembrane domain and a 46 aa cytoplasmic domain containing a PDZ-binding motif and a PKC phosphorylation site (3, 4). Human JAM-C shares 86% aa sequence identity with its mouse homologue. It also shares approximately 36% and 32% aa sequence homology with human JAM-B and JAM-A, respectively (3‑5). Human JAM-C shows widespread tissue expression and the highest levels are found in the placenta, brain, kidney and heart. JAM-C is expressed on endothelial cells of high endothelial venules in human tonsil. It is also expressed on platelets, T-cells and NK cells (3‑5). Unlike other JAM family members, JAM-C forms only weak homotypic interactions. JAM-C binds to JAM-B to facilitate the interactions between JAM-B and the integrin alpha4beta1 (6). This heterotypic interaction between leukocyte JAM-C and endothelial JAM-B may play a role in regulating leukocyte transmigration (5). On platelets, JAM-C is a counter-receptor for the leukocyte integrin Mac-1(CD11b/CD18) (7). JAM-C has also been identified as a strong candidate gene for hypoplastic left heart syndrome (8).

The nomenclature used for the JAM family proteins is confusing. VE-JAM has been referred to in the literature variously as JAM-B or JAM-C. Until further clarification, R&D Systems has adopted the nomenclature where both mouse and human VE-JAM are referred to as JAM-B. Under this system, JAM-C refers to the protein encoded by the gene localized to human chromosome 11.

References

Chavakis, T. et al. (2003) Thromb. Haemost. 89:13.
Aurand-Lions, M. et al. (2001) Blood 98:3699.
Arrate, M.P. et al. (2001) J. Biol. Chem. 276:45826.
Liang, T. et al. (2002) J. Immunol. 168:1618.
Johnson-Leger, C. et al. (2002) Blood 100:25793.
Cunningham, A. et al. (2002) J Biol. Chem. 277:27589.
Santoso, S. et al. (2002) J. Exp. Med. 196:679.
Phillips, H.M. et al. (2002) Genomics 79:475.

Long Name

Junctional Adhesion Molecule C

Entrez Gene IDs

83700 (Human); 83964 (Mouse)

Alternate Names

CD323; JAM-2; JAM3; JAMC; JAM-C; JAM-CFLJ14529; junctional adhesion molecule 3JAM-3; junctional adhesion molecule C

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human JAM-C Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

3 Citations: Showing 1 - 3
Filter your results:

Filter by:

Constitutive and functionally relevant expression of JAM-C on platelets.
Authors: Erpenbeck L, Rubant S, Hardt K, Santoso S, Boehncke WH, Schon MP, Ludwig RJ
Thromb. Haemost., 2010-02-02;103(4):857-9.
Species: Human
Sample Types: Cell Lysates, Whole Cells
Applications: Neutralization, Western Blot
Possible involvement of gap junctions in the barrier function of tight junctions of brain and lung endothelial cells.
Authors: Nagasawa K, Chiba H, Fujita H, Kojima T, Saito T, Endo T, Sawada N
J. Cell. Physiol., 2006-07-01;208(1):123-32.
Species: Porcine
Sample Types: Cell Lysates, Whole Cells
Applications: ICC, Western Blot
Antibody blockade of junctional adhesion molecule-A in rabbit corneal endothelial tight junctions produces corneal swelling.
Authors: Mandell KJ, Holley GP, Parkos CA, Edelhauser HF
Invest. Ophthalmol. Vis. Sci., 2006-06-01;47(6):2408-16.
Species: Rabbit
Sample Types: Whole Tissue
Applications: IHC-Fr